STING Drives CD4 + T Cell Differentiation via JAK – STAT Signalling in Bullous Pemphigoid
Experimental Dermatology · 2026-07 · 35 (7)
DOI: 10.1111/exd.70328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, online erschienen am 17.07.2026. Verfasst von Weiwei Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin…. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Membrane Proteins, Pemphigoid, Bullous, Janus Kinase 1. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Tianjin Key Medical Discipline Construction (Grant No. TJYXZDXK-3-027C), National Natural Science Foundation of China.
Abstract (Originalsprache)
Bullous pemphigoid (BP) is an autoimmune blistering disease with an increasing incidence in recent years; however, the underlying immune regulatory mechanisms remain largely unclear. As a critical signalling hub linking innate and adaptive immunity, stimulator of interferon genes (STING) has recently been implicated in the pathogenesis of various autoimmune diseases and may regulate tissue inflammation and immune homeostasis through modulation of CD4 + T cell responses. In this study, we found that STING expression was significantly increased in lesional skin tissues from patients with BP compared with healthy controls. Transcriptomic analysis further revealed that differentially expressed genes in peripheral blood CD4 + T cells from BP patients were primarily enriched in the JAK–STAT signalling pathway, T cell activation and differentiation, and type I interferon (IFN‐I)‐related pathways. Pharmacological inhibition of STING markedly attenuated the aberrant activation of these signalling pathways. Moreover, qRT‐PCR analysis confirmed that the mRNA levels of STING1, JAK1, and CXCR5 were significantly elevated in BP patients, whereas treatment with the STING inhibitor C176 suppressed the expression of these molecules. Collectively, our findings suggest that STING may contribute to BP immunopathogenesis by regulating the JAK–STAT signalling axis and promoting abnormal CD4 + T cell activation and differentiation, providing new insights into the molecular mechanisms underlying BP and identifying potential therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
- State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Immunology Department, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.
ORCID-Profile: Weiwei Jiang, Mengke Sun, Junchen He, Lizhi Hu
Förderung
- Tianjin Key Medical Discipline Construction (Grant No. TJYXZDXK-3-027C)
- National Natural Science Foundation of China
Zitieren
APA
Jiang, W., Sun, M., He, J., Wang, T., Guo, T., & Hu, L. (2026). STING Drives CD4 + T Cell Differentiation via JAK – STAT Signalling in Bullous Pemphigoid. Experimental Dermatology, 35(7). https://doi.org/10.1111/exd.70328
Vancouver
Jiang W, Sun M, He J, Wang T, Guo T, Hu L. STING Drives CD4 + T Cell Differentiation via JAK – STAT Signalling in Bullous Pemphigoid. Experimental Dermatology. 2026;35(7). doi:10.1111/exd.70328
BibTeX
@article{Jiang2026,
author = {Jiang, Weiwei and Sun, Mengke and He, Junchen and Wang, Tianxue and Guo, Tao and Hu, Lizhi},
title = {STING Drives CD4 + T Cell Differentiation via JAK – STAT Signalling in Bullous Pemphigoid},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {7},
doi = {10.1111/exd.70328}
}
EUVIMED